

Using OFF-X with MetaCore


MetaCore

Exploring safety concerns behind your target of interest

OFF-X is Clarivate's translational safety intelligence portal (separate subscription required). Combine it with MetaCore to anticipate the safety liabilities of potential drug targets that you have identified using MetaCore.

Use Case, using public dataset GSE95153, we explore the biological rationale behind combining BET and MEK inhibitors for NRAS-mutant melanoma.

Upload and analyse your 'omics data into MetaCore to understand the biological processes and hypothesize potential drug targets



Pathway map enrichment shows combination BET + MEK inhibition act synergistically to suppress Aurora B kinase

Network analysis identifies the transcription factor VDRIP as a potential driver of the synergistic drug effect

Click on the drug target MEK-1 to learn more about what it does, and **link to OFF-X targets**:

MEK1(MAP2K1)

Network object | [Build Network](#)

Human		Mouse	Rat
▼ Clarivate Links			
Cortellis Drug Discovery Intelligence		mitogen-activated protein kinase kinase 1	
▼ Clarivate OFF-X Links			
OFF-X Safety alerts		MEK1 , (3784 alerts)	

Welcome to OFF-X™

If you already have a user name and password for OFF-X please use the login option below:

USERNAME

PASSWORD

LOGIN

If you are already a registered user of OFF-X and your organization has OFF-X Single Sign-On access (SSO), please click here:

SSO LOGIN

By logging in you are accepting the following [Terms & Conditions](#). (Last updated September 2021)

Forgot your password? Please [click here](#)


- If you are not yet a subscriber, please contact OFF-X support [using this form](#)
- If your organization has licensed OFF-X under a self-registration mode, [click here](#) to register

- Login,
- Self-register, or
- Request more information

From the **OFF-X safety portal** you can:

- Anticipate safety liabilities for your target of interest
- Track safety concerns over time
- Explore competitor product safety profiles

Three dashboards that you might be interested in checking out initially are:



b. The Translatability dashboard showing level of evidence from preclinical and clinical studies:

OFF-X TARGET/ CLASS SCORE ①	SOC		BIOLOGICAL ROLE & PRECLINICAL PHARMACOLOGICAL EVIDENCE					CLINICAL PHARMACOLOGICAL EVIDENCE					
			TARGET EXPRESSION Source: Human Protein Atlas ①	HUMAN GENETIC VARIANTS ①	KNOCKOUT / KNOCKDOWN ANIMAL DATA ①	IN VITRO DATA / PATIENTS SAMPLE ①	PRECLINICAL ①	PHASE I ①	PHASE II ①	PHASE III ①	CLINICAL REGULATORY ①	POST- MARKETING ①	PHASE NOT SPECIFIED ①
		All System Organ Classes	24	1	0	27 ⑦	418 ⑦	544 ⑫	1360 ⑨	124 ③	533 ④	349 ⑤	583 ⑩
Very High Evidence ②	Investigations					1 ①	87 ⑤ Species: 4	52 ⑧	202 ⑥	12 ②	71 ④	20 ②	41 ⑦
Very High Evidence ②	Gastrointestinal disorders						51 ④ Species: 4	95 ⑪	216 ⑧	28 ③	84 ④	47 ④	83 ⑦
Low Evidence ③	Reproductive system and breast disorders						34 ⑤ Species: 3	1 ①	7 ②		9 ②		1 ①

c. Safety maps:



Particularly useful for novel drug targets (not the case here) where there is no safety information; these maps show class alerts for neighboring targets, helping you to anticipate possible safety liabilities

For more information contact Customer Service at [**LS Product Support**](#)